Related Experiment Videos

[National program for neonatal screening for cystic fibrosis: implementation and preliminary results]

J Navarro1, C Grosskopf, M Vidailhet

  • 1Hôpital Robert-Debré, AP-HP, 48, boulevard Sérurier, 75935 Paris Cedex 19. jean-navarro@rdb.ap-hop-paris.fr

Insights

Neonatal screening for cystic fibrosis (CF) is now a national priority in France. Early detection through blood trypsin and CF mutation analysis offers significant clinical benefits for affected infants.

Area of Science:

  • Biochemistry
  • Genetics
  • Pediatrics

Context:

  • National medical authorities in France have mandated neonatal screening for cystic fibrosis (CF).
  • This decision follows a joint investigation by the French association ADPHE and the national health insurance fund.
  • Advancements in therapeutic strategies underscore the need for early CF detection.

Purpose:

  • To implement a national neonatal screening program for cystic fibrosis.
  • To evaluate the efficacy of a screening method involving immunoreactive trypsin determination followed by CF mutation analysis.
  • To improve clinical outcomes for infants diagnosed with cystic fibrosis.

Summary:

  • The proposed screening protocol involves measuring blood immunoreactive trypsin levels in newborns.
  • Infants with elevated trypsin levels will undergo further testing for common cystic fibrosis (CF) gene mutations.
  • This two-tiered approach aims to accurately identify infants with CF.

Impact:

  • Effective CF detection through this screening method is anticipated.
  • Early diagnosis is expected to lead to substantial clinical benefits for patients.
  • The program aims to improve the long-term health and quality of life for individuals with CF.

Related Concept Videos